Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Applied DNA Sciences ( (APDN) ) has issued an update.
Applied DNA Sciences announced key leadership changes with Judith Murrah appointed as President and Clay Shorrock as President of its subsidiary, LineaRx. The company is undergoing a strategic restructuring to prioritize the production of starting materials for genetic medicines, including the divestiture of its CertainT platform and a focus on its Linea DNA and Linea IVT platforms. The restructuring aims to enhance operational efficiency and shareholder value, with a significant reduction in operating expenses and an increase in manufacturing capabilities.
More about Applied DNA Sciences
Applied DNA Sciences is a leader in PCR-based DNA technologies, focusing on the manufacture of genetic medicines. The company is concentrating its efforts on its Linea DNA and Linea IVT platforms, aiming to expand its presence in the genetic medicine industry.
YTD Price Performance: -98.51%
Average Trading Volume: 4,836,799
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $9.47M
For a thorough assessment of APDN stock, go to TipRanks’ Stock Analysis page.
